Niuliva (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Niuliva, is an Immunoglobulin presented as a unknown/unknown for intravenous use. It provides passive immunity by supplying antibodies that neutralize hepatitis B virus particles, and is employed to prevent infection after exposure and to protect newborns of hepatitis B‑positive mothers.\n\nGNH India supplies Niuliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Niuliva is an immunoglobulin used in the hepatitis B virus pathway to confer passive immunity.\n\n- Post‑exposure prophylaxis: reduces the risk of hepatitis B infection after known or suspected exposure.\n- Newborn protection: prevents vertical transmission of hepatitis B from HBsAg‑positive mothers to infants.\n- Adjunct therapy in acute or chronic hepatitis B: supplies additional antibodies to support the host immune response.

Niuliva may cause a range of adverse reactions following intravenous administration.\n\nCommon Side Effects:\n- Fever or chills\n- Headache\n- Nausea or vomiting\n- Injection‑site erythema or pain\n- Mild urticaria\n- Transient hypertension\n\nSerious or Rare Side Effects:\n- Anaphylactic reaction\n- Serum sickness\n- Acute renal dysfunction\n- Thromboembolic events\n- Severe hypotension\n- Hemolytic anemia

Before using Niuliva, consider the following safety measures.\n\n- Assess HBV serostatus: confirm indication based on exposure or maternal HBsAg status.\n- Monitor for allergic reactions: observe patients during and after infusion for signs of hypersensitivity.\n- Use only in indicated patients: avoid administration without a clear prophylactic or therapeutic need.\n- Caution in IgA deficiency: patients with severe IgA deficiency may be at higher risk of anaphylaxis.\n- Control infusion rate: administer slowly to reduce cardiovascular stress.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Niuliva can interact with other agents that affect immune response or fluid balance.\n\nMajor Interactions (Avoid):\n- Simultaneous hepatitis B vaccine: may diminish vaccine immunogenicity; separate administration by at least 4 weeks.\n\nModerate Interactions (Monitor Closely):\n- Immunosuppressants: may reduce the effectiveness of passive antibodies.\n- Anticoagulants: increased risk of bleeding at infusion sites.\n- Other blood products: potential for volume overload.\n- Live vaccines: consider timing to avoid interference with immune response.